Glucagonoma

Pathophysiology

• Hepatic glycogenolysis and gluconeogenesis (causing hyperglycemia)
• Ketogenesis and lipolysis
• Inhibition of pancreatic and gastric secretions
• Inhibition of gastrointestinal motility

Clinical Features ("4 Ds" + more)

Necrolytic Migratory Erythema (NME) - The Classic Rash

1. Erythematous macules and papules at perioral/intertriginous sites (groin, buttocks, perineum)
2. Expansion into confluent plaques with superficial scale
3. Central superficial bullae that rupture, forming erosions
4. Crusting and healing with hyperpigmentation
5. Lesions appear asynchronously - areas at various stages simultaneously
6. Relapsing and remitting course

Epidemiology & Tumor Characteristics

• Age of onset: primarily >50 years, slight female predominance
• ~90% sporadic; ~10% associated with MEN1
• Almost exclusively pancreatic in origin (vs other NETs)
• Located predominantly in the tail of the pancreas
• Single tumor in the vast majority
• Large at diagnosis: >60% are >3 cm in diameter
• Metastatic at presentation in 42-78% (most commonly to liver, lymph nodes, bone, mesentery)

Diagnosis

• Hypoaminoacidemia
• Normocytic anemia
• Hypocholesterolemia
• Hyperglycemia / diabetic pattern

Treatment

Surgical

• Distal pancreatectomy + splenectomy for localized tail lesions (curative intent)
• Resection even with metastatic disease may be considered (debulking)
• Pre-op: Amino acid infusion or total parenteral nutrition (TPN) improves the dermatologic symptoms and nutritional status before surgery
• Perioperative anticoagulation is recommended given the markedly elevated VTE risk (DVT/PE in up to 33%)

Medical (especially for metastatic/inoperable disease)

• Somatostatin analogues (SSAs) - octreotide or lanreotide: usually highly effective in controlling the rash and hormonal symptoms
• Chemotherapy: streptozotocin + 5-fluorouracil for metastatic disease
• Hepatic artery embolization for liver metastases
• Everolimus or sunitinib (approved for advanced PNETs)

Nutritional

• Amino acid infusions/TPN address hypoaminoacidemia and can dramatically improve NME even before tumor removal

Prognosis

Key Differentials for NME Rash

• Zinc deficiency (acrodermatitis enteropathica)
• Myelodysplastic syndrome
• Short bowel syndrome
• Hepatic cirrhosis
• Celiac disease / malabsorption states
• Inflammatory bowel disease
• Nutritional deficiency states

• Harrison's Principles of Internal Medicine, 22E (2025), Ch. 89 and MEN1 chapter
• Yamada's Textbook of Gastroenterology, 7th ed., pp. 1773-1778
• Sabiston Textbook of Surgery, 21st ed., p. 1594

Somatostatinoma

Pathophysiology

Classic Triad ("Somatostatinoma Syndrome")

Diabetes + Cholelithiasis + Diarrhea/Steatorrhea

Clinical Features

Key Point - Pancreatic vs. Duodenal Presentation

Epidemiology & Tumor Characteristics

• Age: 40-70 years; equal sex distribution
• Usually solitary - multiple tumors suggest MEN1
• Located equally in pancreas and GI tract; most common sites: duodenum > pancreatic head > pancreatic tail
• Pancreatic tumors: mean size 5-6 cm (large at presentation)
• Duodenal tumors: mean size ~2 cm
• Metastatic at presentation in 37-90% (liver, lymph nodes, bone); metastatic risk correlates with tumor size
• Strong association with NF1 (von Recklinghausen's disease) - especially duodenal/ampullary tumors
• Rarely associated with MEN1 (unlike other functional PNETs)

Histological Hallmark

Diagnosis

• Elevated fasting serum somatostatin level - this is the definitive test
• Many NETs stain positive for somatostatin on immunohistochemistry (IHC) without causing the syndrome; therefore, elevated serum levels + clinical symptoms are both required to diagnose true somatostatinoma syndrome
• Provocative testing (arginine, tolbutamide stimulation) does not aid in diagnosis

Treatment

Medical

• Nutrition: Malnutrition from steatorrhea can be severe - may require hyperalimentation/TPN
• Diabetes management: Oral hypoglycemics or insulin depending on severity
• Paradox: Somatostatin analogues (octreotide, lanreotide) have shown some benefit in reducing somatostatin release and mitigating diarrhea and diabetes, despite acting on the same receptor - the benefit is thought to come from preferential receptor subtype binding
• Treatment of cholelithiasis as needed

Surgical

• Surgery is recommended for all patients with localized disease - can be curative
• For NF1-associated periampullary somatostatinomas presenting as smaller, localized tumors, surgery is particularly effective
• The potential role of SSAs as primary treatment is questionable given that the tumor itself produces somatostatin

Metastatic Disease

• Streptozotocin + 5-fluorouracil (chemotherapy)
• Hepatic artery embolization for liver metastases
• Everolimus or sunitinib for advanced PNETs
• Peptide receptor radionuclide therapy (PRRT) with Lu-177 DOTATATE for somatostatin receptor-positive disease

Key Distinguishing Points vs. Other Functional PNETs

• Harrison's Principles of Internal Medicine, 22E (2025)
• Yamada's Textbook of Gastroenterology, 7th ed., pp. 1774-1778
• Sabiston Textbook of Surgery, 21st ed., p. 1594
• Fischer's Mastery of Surgery, 8th ed.

Somatostatinoma - Detailed Review

Overview & Historical Background

Physiology of Somatostatin - Why the Syndrome Makes Sense

Anatomical Location

1. Duodenum (most common GI site, often periampullary)
2. Pancreatic head (60-80% of pancreatic somatostatinomas occur here)
3. Pancreatic tail
4. Rarely: jejunum, other intestinal sites

Key Clinical Features

The Classic Triad (Somatostatinoma Syndrome)

Diabetes Mellitus + Cholelithiasis + Diarrhea/Steatorrhea

Detailed Symptom Profile

• Develops in over 1/3 of patients due to somatostatin's inhibition of insulin secretion
• Severity varies widely: mild glucose intolerance controlled by oral hypoglycemics at one end, insulin-dependent diabetes at the other
• Usually milder than type 1 DM because glucagon secretion is simultaneously inhibited (reducing the counter-regulatory hyperglycemic response)

• Present in 16-64% of patients
• Due to two mechanisms: (a) inhibition of CCK release, and (b) direct inhibition of gallbladder contractility
• Results in bile stasis and gallstone formation
• Right upper quadrant pain is a common presenting complaint (25% of cases, per Schwartz's)
• Jaundice occurs in ~25% - from either gallstone disease or direct periampullary tumor compression of the bile duct

• Due to multiple mechanisms: inhibited pancreatic enzyme secretion, inhibited bicarbonate output, inhibited gallbladder emptying, reduced lipid absorption
• Can range from loose stools to florid steatorrhea with bulky, fatty, malodorous stools
• Contributes to significant weight loss

• Present in 20-30% of cases
• Multifactorial: malabsorption, steatorrhea, reduced nutrient absorption

• From inhibited gastric acid secretion; usually subclinical

• Commonly present; mechanism likely related to malabsorption and nutritional deficiency

• The most common presenting complaint in surgical series (25%)
• Can be from cholelithiasis, biliary obstruction, or local tumor mass effect

• In ~25% at presentation
• Particularly with periampullary or large pancreatic head tumors compressing the bile duct

Tumor Biology & Histopathology

Pancreatic vs. Duodenal Somatostatinomas - Key Differences

Psammoma Bodies

Size & Malignancy

• Pancreatic tumors are almost always large at diagnosis (mean 5-6 cm)
• Tumor size is the strongest predictor of metastatic spread
• Metastases occur to: liver, lymph nodes, bone
• Overall metastatic rate at presentation: 37-90%

Genetic Associations

1. Neurofibromatosis Type 1 (NF1 / von Recklinghausen's Disease)

• The strongest genetic association for somatostatinoma
• ~1% of NF1 patients develop duodenal NETs, the majority periampullary
• In a 20-year review of periampullary/duodenal neoplasms in NF1 (Relles et al., 2010): somatostatinoma was the most common tumor type at 40%, followed by GIST (34%), adenocarcinoma (8%), carcinoid (6%)
• NF1-associated somatostatinomas:
  • Usually periampullary/duodenal (not pancreatic)
  • Smaller (mean 2.8 cm vs. 5.9 cm)
  • Lower rate of metastases (30% vs. 71%)
  • High rate of psammoma bodies (61% vs. 0%)
  • Rarely cause the full somatostatinoma syndrome - come to attention due to biliary obstruction, pancreatitis, or bleeding
  • Behave more like sporadic duodenal somatostatinomas

2. MEN1 (Multiple Endocrine Neoplasia Type 1)

• Somatostatinomas are only rarely associated with MEN1, in contrast to insulinoma, gastrinoma, and glucagonoma
• Multiple tumors should raise suspicion for MEN1 (somatostatinomas are otherwise almost always solitary)

3. Polycythemia-Paraganglioma/Pheochromocytoma-Somatostatinoma Syndrome

• A rare inherited syndrome, primarily associated with duodenal somatostatinomas
• Associated with VHL or EPAS1 (HIF-2α) mutations
• Should be considered when somatostatinoma co-exists with pheochromocytoma or paraganglioma

Diagnosis

Clinical Suspicion

• Classic triad (DM + gallstones + steatorrhea) is present together
• Periampullary/duodenal mass found - especially in a patient with NF1
• Psammoma bodies found on biopsy of a duodenal NET
• Any duodenal lesion in an NF1 patient

Biochemical Diagnosis

• Elevated fasting serum somatostatin-like immunoreactivity in plasma - required for diagnosis of the syndrome
• Normal upper limit: typically <120 pg/mL
• Somatostatinoma: usually >500 pg/mL; Schwartz's states levels are usually >10 ng/mL (10,000 pg/mL) in confirmed cases
• Must also confirm elevated levels in the resected tumor tissue

• Small cell lung cancer
• Medullary thyroid carcinoma
• Pheochromocytomas
• Paragangliomas

Provocative Testing

• Provocative tests (arginine stimulation, tolbutamide stimulation) do not aid diagnosis and are not recommended

Supporting Labs

• Hyperglycemia (often mild-moderate)
• Hypochlorhydria on gastric pH studies
• Elevated fecal fat (steatorrhea confirmation)
• Imaging: gallstones on ultrasound

Imaging & Localization

1. CT abdomen/pelvis with contrast - initial modality; pancreatic head mass or periampullary lesion
2. MRI - superior soft tissue detail for pancreatic lesions
3. Somatostatin receptor scintigraphy (Octreoscan) or Ga-68 DOTATATE PET-CT - functional imaging to assess somatostatin receptor expression, stage disease, identify metastases; also guides PRRT candidacy
4. Endoscopic ultrasound (EUS) - excellent for small duodenal or pancreatic head lesions; allows FNA biopsy
5. Upper GI endoscopy - for periampullary and duodenal tumors

Treatment

Surgical (Primary Treatment)

• Surgery is recommended for all patients with localized disease - can be curative
• Attempt at complete excision warranted even in most metastatic cases (debulking)
• Cholecystectomy should be performed at the same time given the high rate of cholelithiasis
• Specific operations:
  • Pancreaticoduodenectomy (Whipple) for pancreatic head or periampullary tumors
  • Distal pancreatectomy for body/tail pancreatic tumors
  • Local duodenal excision for small duodenal tumors (if feasible)
• In NF1-associated periampullary lesions presenting as small, localized tumors, surgery is particularly effective

Medical / Symptom Control

• Somatostatin analogues (SSAs) - octreotide (10-30 mg IM every 4 weeks) or lanreotide (90-120 mg deep SC monthly):
  • Paradoxically can improve symptoms by decreasing somatostatin release (via preferential receptor subtype binding)
  • Shown to reduce diarrhea and ameliorate diabetes
  • Also have antiproliferative effects on NETs
• Diabetes management: oral hypoglycemics or insulin based on severity
• Nutritional support: steatorrhea-related malnutrition can be severe; may require hyperalimentation/TPN, pancreatic enzyme replacement therapy (PERT)
• Pancreatic enzyme replacement for steatorrhea/maldigestion

Management of Metastatic / Unresectable Disease

1. SSAs (octreotide LAR, lanreotide) - antiproliferative + symptomatic
2. Chemotherapy: streptozotocin + 5-fluorouracil (or streptozotocin + doxorubicin)
3. Targeted therapy:
   • Everolimus (mTOR inhibitor) - approved for advanced PNETs
   • Sunitinib (VEGFR inhibitor) - approved for advanced PNETs
4. Peptide Receptor Radionuclide Therapy (PRRT): Lu-177 DOTATATE (Lutathera) - for somatostatin receptor-positive disease; high uptake on DOTATATE PET predicts response
5. Liver-directed therapies for hepatic metastases:
   • Transarterial embolization (TAE)
   • Transarterial chemoembolization (TACE)
   • Radioembolization (TARE) with Yttrium-90
   • Percutaneous/surgical ablation (radiofrequency or microwave) for oligometastatic disease
6. Surgical debulking if >90% tumor burden reducible - 5-year survival 60-75% in selected patients

Important Surgical Note

Prognosis

• Location (duodenal > pancreatic in outcome)
• Tumor size (strongest predictor of metastatic spread)
• Presence of liver metastases at diagnosis
• Resectability of primary tumor

Differential Diagnosis of the Somatostatinoma Syndrome

Summary - High-Yield Points

• Incidence: 1 in 40 million - the rarest functional PNET
• Classic triad: Diabetes + Cholelithiasis + Steatorrhea
• Mechanism: somatostatin inhibits insulin, CCK, pancreatic enzymes, bile
• Location: pancreas = GI tract (duodenum most common GI site)
• Pancreatic tumors: large (5-6 cm), high metastatic rate (70-90%), cause the full syndrome
• Duodenal tumors: smaller (2 cm), lower metastatic rate (30-40%), psammoma bodies, rarely cause syndrome
• Strong association with NF1 (duodenal/periampullary - most common periampullary tumor in NF1)
• Rarely associated with MEN1
• Diagnosis: elevated fasting serum somatostatin + clinical syndrome + imaging
• Histology clue: psammoma bodies in duodenal tumors
• Treatment: surgery (curative intent) + cholecystectomy; SSAs for symptoms; PRRT/everolimus/sunitinib for advanced disease
• Prognosis: duodenal (5-yr >80%) far better than pancreatic (5-yr <50%)

• Harrison's Principles of Internal Medicine, 22E (2025)
• Goldman-Cecil Medicine, International Edition
• Yamada's Textbook of Gastroenterology, 7th ed.
• Sabiston Textbook of Surgery, 21st ed.
• Schwartz's Principles of Surgery, 11th ed.
• Fischer's Mastery of Surgery, 8th ed.
• Sleisenger and Fordtran's GI and Liver Disease
• Mulholland and Greenfield's Surgery, 7th ed.